Oral Ivermectin for Chikungunya Viral Infection

Clinical Syndrome Clinical Trial

Official title:
A Randomized Controlled Trial of Oral Ivermectin for Patients With Chikungunya Viral Infection During Urban Outbreak in Southern Thailand

Status Completed

Clinical Trial Summary

Chikungunya viral infection (CVI) is a mosquito-borne infection, caused by chikungunya virus (CHIKV), an alphavirus, belonging to the family Togaviridae. This infection causes febrile illness associated with high fever, rash, acute deliberating and persistent arthralgia. There is no licensed vaccine or specific treatment for this infection. Ivermectin (IVM), commonly-used antiparasitic, has been demonstrated to inhibit replication of CHIKV.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06259383
Study type	Interventional
Source	Prince of Songkla University
Contact
Status	Completed
Phase	Phase 3
Start date	January 1, 2018
Completion date	January 26, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04571021` - Implementation of the Individual Danish Emergency Process Triage	N/A
Completed	`NCT05060692` - Changes of NLF in Serum of Long COVID Patients
Recruiting	`NCT06102655` - Effect and Mechanism of Jiajian Guishen Formulation on Premature Ovarian Insufficiency Based on Metabolomics	Early Phase 1
Recruiting	`NCT06109337` - Immunoprofilling of Peripheral Blood Mononuclear Cells in Children With Attention Deficit/Hyperactivity Disorder